Compare HLLY & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLLY | CYPH |
|---|---|---|
| Founded | 1903 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.6M | 321.1M |
| IPO Year | 2020 | 2019 |
| Metric | HLLY | CYPH |
|---|---|---|
| Price | $2.50 | $2.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $4.11 | N/A |
| AVG Volume (30 Days) | 1.2M | ★ 13.3M |
| Earning Date | 11-05-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 180.00 | 103.87 |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $613,514,000.00 | $1,500,000.00 |
| Revenue This Year | $0.79 | N/A |
| Revenue Next Year | $4.53 | $408.92 |
| P/E Ratio | $24.95 | ★ N/A |
| Revenue Growth | ★ 1.87 | N/A |
| 52 Week Low | $2.05 | $0.49 |
| 52 Week High | $4.48 | $4.19 |
| Indicator | HLLY | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 48.95 | 40.45 |
| Support Level | $2.42 | $0.65 |
| Resistance Level | $2.70 | $3.42 |
| Average True Range (ATR) | 0.20 | 0.39 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 49.46 | 7.69 |
Holley Inc designs, manufactures, and distributes high-performance automotive aftermarket products to car and truck enthusiasts in the United States, Canada and Europe. It manufactures a diversified line of performance automotive products, including carburetors, fuel pumps, fuel injection systems, nitrous oxide injection systems, superchargers, exhaust headers, mufflers, distributors, ignition components, engine tuners and automotive performance plumbing products. It also manufactures exhaust products as well as shifters, converters, transmission kits, transmissions, tuners and automotive software. The company markets its products under brands such as Holley, Holley EFI, MSD, Simpson, Flowmaster, EDGE, Cataclean, and Accel, among others. It operates in single segment.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.